LIAISON PLEXÂ Gram-Positive Blood Culture Assay Gets 510(k) Nod
Diasorin has received FDA 510(k) clearance for its LIAISON PLEX Gram-Positive Blood Culture Assay, completing its syndromic blood culture portfolio.
Diasorin has received FDA 510(k) clearance for its LIAISON PLEX Gram-Positive Blood Culture Assay, completing its syndromic blood culture portfolio.
The CLP May/June 2023 Tech Guide that appears in Clinical Lab Products (CLP) features a wide-range of products from top laboratory providers.
Through the acquisition, DiaSorin will gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering.
The test is highly specific to covid-19 and targets several regions of the viral genome to minimize the impact on performance should there be possible future mutations.
Read MoreThe product is expected to be CE marked and submitted to the FDA by the end of March 2020 to consider for emergency use authorization.
Read MoreThe moderate-complexity assay is designed to detect varicella-zoster virus DNA from cutaneous and mucocutaneous swab specimens.
Read MoreThe test enables highly automated screening for latent tuberculosis.
Read MoreDiaSorin Molecular has released a new primer pair that targets the yeast Candida auris, for use in creating laboratory-developed molecular tests
Read MoreInclusion of VZV along with HSV-1 and HSV-2 testing may enable clinicians to provide improved therapeutic decisions and advice.
Read MoreThis month’s Product News section features products from Qiagen, ELITechGroup Biomedical Systems, and DiaSorin Molecular.
Read MoreWith clearance for additional sample types, the DiaSorin Molecular Simplexa HSV 1 & 2 assay now claims the most comprehensive sample type coverage for HSV testing on the market.
Read MoreThe offerings join DiaSorin Molecular’s menu of more than 60 molecular reagents for bacterial, fungal, and viral targets.
Read MoreThis month’s issue features laboratory reagents and consumables from such companies as Audit Microcontrols, Bio-rad Laboratories, and Diasorin Molecular.
Read MoreBy purchasing Quest Diagnostics’ immunology and molecular diagnostic products business, DiaSorin looks to boost its presence in the growing market for infectious disease testing.
Read MoreDiaSorin and Beckman Coulter have signed a partnership agreement for distribution of automated hepatitis and HIV tests and instruments in China.
Read More